로딩 중…
지수 로딩 중…
ILYANG PHARMACEUTICAL CO.,LTD
007570· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,850-2.61%
2026-09-18
Financials
Valuation Metrics
ILYANG PHARMACEUTICAL CO.,LTD's Market Cap is ₩1532B. At end of 2025 it was ₩2844B. Ranked #1008 of 2,421 in KR market (top 42%), #500 of 781 on KOSPI (top 64%), #114 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 153.25B KRW | KR#1,008/2,421 Sec#114/231 |
| Revenue | 277.96B KRW | KR#863/2,421 Sec#41/231 |
| Net Income | 17.36B KRW | KR#758/2,421 Sec#51/231 |
| Total Assets | 451.72B KRW | KR#822/2,421 Sec#49/231 |
| Net Assets | 256.94B KRW | KR#811/2,421 Sec#52/231 |
| Employees | 668 | KR#375/2,421 Sec#32/231 |
| Value | ||
| P/E | 8.83x | KR#724/2,421 Sec#34/231 |
| P/B | 0.60x | KR#982/2,421 Sec#52/231 |
| PEG | 0.13x | KR#468/2,421 Sec#27/231 |
| P/S | 0.55x | KR#990/2,421 Sec#44/231 |
| FCF Yield | 4.13% | KR#907/2,421 Sec#52/231 |
| Profitability | ||
| ROE | 6.76% | KR#907/2,421 Sec#62/231 |
| ROA | 3.84% | KR#909/2,421 Sec#75/231 |
| Op. Margin | -4.94% | KR#1,852/2,421 Sec#123/231 |
| Revenue Growth | 19.63% | KR#565/2,421 Sec#53/231 |
| Earnings Growth | 67.20% | KR#491/2,421 Sec#32/231 |
| Financial Health | ||
| Debt Ratio | 75.81% | KR#1,291/2,421 Sec#155/231 |
| Total Debt | 177.93B KRW | KR#545/2,421 Sec#29/231 |
| FCF | 6.32B KRW | KR#841/2,421 Sec#55/231 |
| Cash | 12.87B KRW | KR#1,545/2,421 Sec#126/231 |
| Current Ratio | 0.88x | KR#1,862/2,421 Sec#182/231 |
| Dividend | ||
| Div. Yield | 1.97% | KR#883/2,421 Sec#44/231 |
| Div. Growth | 3.33% | KR#669/2,421 Sec#36/231 |
| Performance | ||
| 1Y Return | -46.23% | KR#1,974/2,421 Sec#173/231 |
| 1M Return | -6.10% | KR#1,874/2,421 Sec#152/231 |
| From 52W High | -51.66% | KR#1,476/2,421 Sec#112/231 |
| 1Y MDD | -49.86% | KR#988/2,421 Sec#82/231 |
| Trading | ||
| Volume | 32,809 shares | KR#1,340/2,421 Sec#129/231 |
| Trading Value | 258.4M KRW | KR#1,172/2,421 Sec#117/231 |
| Foreign Own. | 5.49% | KR#797/2,421 Sec#74/231 |
| Per Share | ||
| EPS | 889 KRW | KR#771/2,421 Sec#53/231 |
| BPS | 13,162 KRW | KR#789/2,421 Sec#53/231 |
Company Info
동사는 1946년 설립, 1971년 법인 전환 후 2009년 일양바이오팜(주) 설립과 함께 중국 시장 진출을 위해 일양약품(길림)유한공사를 신설하였음. 제14호 신약 놀텍, 제18호 신약 슈펙트, 계절독감백신 등의 전문의약품과 원비디 등 일반의약품, 원료의약품, 건강보조식품을 제조판매하고 있음. 시장점유율 증대를 위한 R&D 투자와 글로벌 혁신의약품 개발을 최우선으로 하고 있음. 일양약품는 1946년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.